Epub 2018/11/13
The drug is considered not to represent an unreasonable risk
The studies demonstrated body composition improvements without effects on serum IGF-1 levels, carbohydrate metabolism, or insulin sensitivity
BPC-157s effects on multiple neurotransmitter systems create theoretical interaction points with psychiatric medications, yet interactions are not well studied. Particular concerns include serotonin syndrome risk when combined with SSRIs (since BPC-157 modulates serotonin in complex regional patterns), unpredictable effects on dopaminergic medications (antipsychotics, ADHD treatments, Parkinsons medications), and unknown interactions with benzodiazepines despite the animal studies showing tolerance prevention
Reed MC, Nijhout HF, Sparks R, Ulrich CM: A Mathematical model of the methionine cycle
Protect the product from excess heat or direct sunlight